SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults.

Publication Title

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Authors

Matthew E Levy
Evanette Burrows
Vanessa Chilunda
Pamala A Pawloski
Phillip R Heaton
Joseph Grzymski
Jason D Goldman, Providence St. Joseph Health System, Renton, Washington, USA., Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, Washington, USA.Follow
Lisa M McEwen
Dana Wyman
Andrew Dei Rossi
Hang Dai
Magnus Isaksson
Nicole L Washington
Tracy Basler
Kevin Tsan
Jason Nguyen
Jimmy Ramirez
Efren Sandoval
William Lee
James Lu
Shishi Luo

Document Type

Article

Publication Date

1-3-2024

Keywords

washington; swedish; renton; covid-19

Abstract

Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

Specialty/Research Institute

Infectious Diseases

Specialty/Research Institute

Population Health

DOI

10.1093/cid/ciad796